sur TME PHARMA N.V. (isin : NL0015000YE1)
TME Pharma strengthens its liquidity contract with Invest Securities
On April 10, 2025, TME Pharma NV, a specialist in oncology biotechnology, announced that it had injected an additional €5,000 into its liquidity contract managed by Invest Securities. This contribution aims to stabilize cash and securities resources, in accordance with Article 4 of AMF Decision No. 2021-01. This increase in resources is in addition to a cash balance of €13,401.54 and 97,807 shares. For comparison, at the end of 2024, its account showed 73,874 shares and €9,914.70 in cash.
TME Pharma, listed on Euronext Growth Paris, focuses on developing therapies targeting the tumor microenvironment. This strategy is part of its mission to develop treatments for the most aggressive cancers in Europe and the United States.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de TME PHARMA N.V.